Limba
|
Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.
Price | 16.249,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28. |